Filing Details

Accession Number:
0000903423-19-000271
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-07-02 16:13:23
Reporting Period:
2019-07-01
Accepted Time:
2019-07-02 16:13:23
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1679363 Morphic Holding Inc. MORF Pharmaceutical Preparations (2834) X0
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1131399 Plc Glaxosmithkline 980 Great West Road
Brentford Middlesex X0 TW8 9GS
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-07-01 1,469,950 $0.00 1,469,950 No 4 C Indirect See Footnote
Common Stock Acquisiton 2019-07-01 830,489 $0.00 2,300,439 No 4 C Indirect See Footnote
Common Stock Acquisiton 2019-07-01 333,333 $15.00 2,633,772 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 P Indirect See Footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A preferred stock Disposition 2019-07-01 1,469,950 $0.00 1,469,950 $0.00
Common Stock Series B preferred stock Disposition 2019-07-01 830,489 $0.00 830,489 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. S.R. One, Limited acquired 333,333 common shares of the Issuer in connection with the Issuer's initial public offering.
  2. Each share of the Issuer's Series A Preferred Stock automatically converted into one share of the Issuer's Common Stock on July 1, 2019 in connection with the closing of the Issuer's sale of its Common Stock in its initial public offering (the 'IPO") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date..
  3. Each share of the Issuer's Series B Preferred Stock automatically converted into one share of the Issuer's Common Stock on July 1, 2019 in connection with the closing of the Issuer's sale of its Common Stock in IPO pursuant to the Registration Statement, and had no expiration date.
  4. The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").